Literature DB >> 9351972

Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines.

Z P Chen1, A Malapetsa, A McQuillan, D Marcantonio, V Bello, G Mohr, J Remack, T P Brent, L C Panasci.   

Abstract

We examined the O6-methylguanine-DNA methyltransferase (MGMT) protein as well as MGMT activity levels and the excision repair cross-complementing rodent repair deficiency gene, ERCC2 (XPD), protein levels in 14 human tumor cell lines not selected for chloroethylnitrosourea (CENU) resistance. These results were compared with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) cytotoxicity and UV light sensitivity. MGMT protein correlated significantly with MGMT activity (r = 0.9497, p = 0.0001). There was no significant linear correlation between BCNU cytotoxicity and MGMT content as determined by both Western analysis (r = 0.139, p = 0. 6348) and activity assay (r = 0.131, p = 0.6515). However, MGMT-rich cell lines were found to be more resistant than MGMT-poor cell lines to BCNU (t = 2.2375, p = 0.0225) but not to UV (t = 1.1734, p = 0.1317). Furthermore, the most BCNU-sensitive cell lines were all MGMT-poor. UV sensitivity was significantly correlated to BCNU cytotoxicity (r = 0.858, p = 0.0001). Significant correlations were found between ERCC2 protein levels and BCNU cytotoxicity (r = 0.786, p = 0.0009) or UV sensitivity (r = 0.874, p = 0.0001). Our results confirm that MGMT plays an important role in CENU resistance, but not in UV resistance. The correlation of UV sensitivity with BCNU cytotoxicity suggests that nucleotide excision repair is an important modifying factor of MGMT-mediated innate CENU resistance in human tumor cell lines, especially in highly resistant cell lines. ERCC2 may be implicated in this process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351972     DOI: 10.1124/mol.52.5.815

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.

Authors:  Li Jiao; Manal M Hassan; Melissa L Bondy; James L Abbruzzese; Douglas B Evans; Donghui Li
Journal:  Cancer Lett       Date:  2006-02-03       Impact factor: 8.679

Review 2.  O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

Authors:  John R Silber; Michael S Bobola; A Blank; Marc C Chamberlain
Journal:  Biochim Biophys Acta       Date:  2012-01-08

3.  The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.

Authors:  Jian Zhang; Li-Xin Qiu; Shiang-Jiin Leaw; Xi-Chun Hu; Jian-Hua Chang
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

4.  Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.

Authors:  Z P Chen; J Pan; Q Huang; Z F Sun; L Y Zhou; A D Wang
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

5.  Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.

Authors:  Stephen T Keir; Christopher L Morton; Catherine Billups; Malcolm A Smith; Peter J Houghton; Sridharan Gururangan
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

6.  Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma.

Authors:  Huayun Chen; Cuijie Shao; Hongliu Shi; Yonggao Mu; Ke Sai; Zhongping Chen
Journal:  J Neurooncol       Date:  2006-12-07       Impact factor: 4.506

7.  Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer.

Authors:  Benjamín Gómez-Díaz; María DE LA Luz Ayala-Madrigal; Melva Gutiérrez-Angulo; Aura Erazo Valle-Solis; Luis Miguel Linares-González; Roberto González-Guzmán; David Cruz-Guillén; Ana Lilia Cedeño-Garcidueñas; Patricia Canto; Luz Berenice López-Hernández
Journal:  Oncol Lett       Date:  2015-01-26       Impact factor: 2.967

8.  Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis.

Authors:  Enjiao Zhang; Zhigang Cui; Zhongfei Xu; Weiyi Duan; Shaohui Huang; Xuexin Tan; Zhihua Yin; Changfu Sun; Li Lu
Journal:  BMC Cancer       Date:  2013-12-12       Impact factor: 4.430

9.  ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females.

Authors:  Zhihua Yin; Meng Su; Xuelian Li; Mingchuan Li; Rui Ma; Qincheng He; Baosen Zhou
Journal:  J Exp Clin Cancer Res       Date:  2009-12-14

10.  Fluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug Response.

Authors:  Andrew A Beharry; Zachary D Nagel; Leona D Samson; Eric T Kool
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.